CBO Peter Marschel to Lead HubXchange Roundtable on Computational Peptide Design CSO Dr. Barbara Hibner and CTO Dr. Michael Lipp to Co-Present at Peptide-Based Therapeutics Summit; Advisor Dr. Bradley Pentelute to Deliver Opening Remarks CAMBRIDGE, Mass., April 27, 2026 /PRNewswire/ -- Decoy

Highly differentiated AI-powered D-MAV discovery platform targeting drug discovery in the multi-billion-dollar antiviral markets Company to participate in Virtual Investor Closing Bell event to discuss path forward today at 4:00 PM ET. Access the event here CAMBRIDGE, Mass.

Live video webcast with Rick Pierce, Chief Executive Officer of Decoy Therapeutics, on Thursday, April 9 th at 4:00 PM ET Register for the event here CAMBRIDGE, Mass. and HOUSTON, April 6, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company

CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), announces that on March 31, 2026 the Company received notification from the Nasdaq Stock Market LLC that it has regained compliance with Listing Rule 5550(a)(2), the Minimum

Partnership supported by funding from Google Cloud will increase Decoy's computational peptide design bandwidth by 25-100x CAMBRIDGE, Mass. and HOUSTON, March 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable

CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate therapeutics, today announced that it will effect a 1-for-12 reverse stock split at 5:00 p.m.

-  Connect with the Company on Webull here CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it

– Live video webcast on Tuesday, February 10 th at 1:20 PM EST CAMBRIDGE, Mass. and HOUSTON, Feb. 5, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today

Access the "What This Means" segment here CAMBRIDGE, Mass. and HOUSTON, Feb. 4, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it

Decoy Therapeutics will use the platform, with funding support from the Gates Foundation, to provide widespread access to peptide-conjugate antivirals from Decoy's IMP³ACT™   platform for low- and middle-income countries. CAMBRIDGE, Mass. and HOUSTON, Jan.